Serial 1H-NMR Spectroscopy Study of Metabolic Impairment in Primates Chronically Treated with the Succinate Dehydrogenase Inhibitor 3-Nitropropionic Acid

Previous studies in primates have shown that chronic systemic administration of the succinate dehydrogenase (SDH) inhibitor, 3-nitropropionic acid (3NP), replicates most of the motor, cognitive, and histopathological features of Huntington's disease. In the present study, serial 1H-NMR spectroscopy (1H-MRS) assessment of striatal and occipital cortex concentrations of N-acetylaspartate, phosphocreatine/creatine, choline, and lactate, were obtained every 2-weeks during the entire course of a chronic 3NP treatment in baboons. A region-selective increase in lactate was detected in the striatum of the 3NP-treated animals, either immediately before or in conjunction with a lesion in the dorsolateral putamen detected by T2-MR imaging. Absolute 1H-MRS quantitation demonstrated a progressive and region-specific decrease in striatal N-acetylaspartate, creatine, and choline, occuring as early as 3 weeks before the first detection of lactate. These results demonstrate that 1H-MRS can be used to monitor early stages of brain metabolic impairment. In addition, given that 3NP-induced SDH inhibition following systemic injection similarly affects all brain regions, the striatal selective decreases in N-acetylaspartate or creatine concentrations are not simply related to the level of mitochondrial impairment but to a preferential vulnerability of the striatum to 3NP-induced toxicity.

[1]  J. Vion-Dury,et al.  Reversal of brain metabolic alterations with zidovudine detected by proton localised magnetic resonance spectroscopy , 1995, The Lancet.

[2]  R. Albin,et al.  Chronic Administration of Malonic Acid Produces Selective Neural Degeneration and Transient Changes in Calbindin Immunoreactivity in Rat Striatum , 1995, Experimental Neurology.

[3]  N. Herschkowitz,et al.  N-acetyl-L-aspartate is a major source of acetyl groups for lipid synthesis during rat brain development. , 1991, Developmental neuroscience.

[4]  F. Yatsu,et al.  ACETATE METABOLISM IN THE NERVOUS SYSTEM. N‐ACETYL‐l‐ASPARTIC ACID AND THE BIOSYNTHESIS OF BRAIN LIPIDS * , 1966, Journal of neurochemistry.

[5]  M Noble,et al.  Specific Expression of N‐Acetylaspartate in Neurons, Oligodendrocyte‐Type‐2 Astrocyte Progenitors, and Immature Oligodendrocytes In Vitro , 1992, Journal of neurochemistry.

[6]  F. Condé,et al.  Partial Inhibition of Brain Succinate Dehydrogenase by 3‐Nitropropionic Acid Is Sufficient to Initiate Striatal Degeneration in Rat , 1998, Journal of neurochemistry.

[7]  Françoise Condé,et al.  Fetal striatal allografts reverse cognitive deficits in a primate model of Huntington disease , 1998, Nature Medicine.

[8]  B. Rosen,et al.  Energy metabolism defects in Huntington's disease and effects of coenzyme Q10 , 1997, Annals of neurology.

[9]  B. Hassel,et al.  Selective Inhibition of the Tricarboxylic Acid Cycle of GABAergic Neurons with 3‐Nitropropionic Acid In Vivo , 1995, Journal of neurochemistry.

[10]  M. Peschanski,et al.  Chapter 35 Prospectives for cell and gene therapy in Huntington's disease , 1998 .

[11]  B R Rosen,et al.  1H NMR spectroscopy studies of Huntington's disease , 1998, Neurology.

[12]  E. Brouillet,et al.  Effects of chronic MPTP and 3-nitropropionic acid in nonhuman primates. , 1995, Current opinion in neurology.

[13]  O Henriksen,et al.  In vivo quantification of brain metabolites by 1H-MRS using water as an internal standard. , 1993, Magnetic resonance imaging.

[14]  P. Matthews,et al.  Reversible decreases in N‐acetylaspartate after acute brain injury , 1995, Magnetic resonance in medicine.

[15]  J. Frahm,et al.  On the N‐acetyl methyl resonance in localized 1H NMR spectra of human brain In Vivo , 1991, NMR in biomedicine.

[16]  H. Tallan.  Studies on the distribution of N-acetyl-L-aspartic acid in brain. , 1957, The Journal of biological chemistry.

[17]  D. Wallace.  Mitochondrial genetics: a paradigm for aging and degenerative diseases? , 1992, Science.

[18]  S. W. Davies,et al.  Exon 1 of the HD Gene with an Expanded CAG Repeat Is Sufficient to Cause a Progressive Neurological Phenotype in Transgenic Mice , 1996, Cell.

[19]  William H. Oldendorf,et al.  N-Acetyl-L-Aspartic acid: A literature review of a compound prominent in 1H-NMR spectroscopic studies of brain , 1989, Neuroscience & Biobehavioral Reviews.

[20]  M. Beal,et al.  Chronic 3-Nitropropionic Acid Treatment in Baboons Replicates the Cognitive and Motor Deficits of Huntington’s Disease , 1996, The Journal of Neuroscience.

[21]  B D Ross,et al.  Absolute Quantitation of Water and Metabolites in the Human Brain. I. Compartments and Water , 1993 .

[22]  D. Johns.  Seminars in medicine of the Beth Israel Hospital, Boston. Mitochondrial DNA and disease. , 1995, The New England journal of medicine.

[23]  A. Ludolph,et al.  Decreased N-acetyl-aspartate/choline ratio and increased lactate in the frontal lobe of patients with Huntington's disease: a proton magnetic resonance spectroscopy study. , 1997, Journal of neurology, neurosurgery, and psychiatry.

[24]  B D Ross,et al.  Absolute Quantitation of Water and Metabolites in the Human Brain. II. Metabolite Concentrations , 1993 .

[25]  G. Barker,et al.  Proton MRS in Huntington's disease , 1994, The Lancet.

[26]  D. Brooks,et al.  Evidence for glutamate excitotoxicity in Huntington's disease with proton magnetic resonance spectroscopy , 1994, The Lancet.

[27]  M. Beal,et al.  Chronic mitochondrial energy impairment produces selective striatal degeneration and abnormal choreiform movements in primates. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[28]  H. Möller,et al.  Localized proton NMR spectroscopy in the striatum of patients with idiopathic parkinson's disease: a multicenter pilot study , 1995 .

[29]  B. Miller.  A review of chemical issues in 1H NMR spectroscopy: N‐acetyl‐l‐aspartate, creatine and choline , 1991, NMR in biomedicine.

[30]  B J Soher,et al.  Quantitation of proton NMR spectra of the human brain using tissue water as an internal concentration reference , 1993, NMR in biomedicine.

[31]  Peter M. G. Munro,et al.  Inhibition of N-acetylaspartate production: implications for 1H MRS studies in vivo. , 1996, Neuroreport.

[32]  D. Brooks,et al.  Proton magnetic resonance spectroscopy in Huntington's disease: Evidence in favour of the glutamate excitotoxic theory? , 1996, Movement disorders : official journal of the Movement Disorder Society.

[33]  B. Rosen,et al.  Evidence for irnnairment of energy metabofism in vivo in Huntington's disease using localized 1H NMR spectroscopy , 1993, Neurology.

[34]  R. Albin,et al.  Alternative excitotoxic hypotheses , 1992, Neurology.

[35]  O Henriksen,et al.  In vivo quantitation of metabolite concentrations in the brain by means of proton MRS , 1995, NMR in biomedicine.

[36]  J. Frahm,et al.  Absolute concentrations of metabolites in the adult human brain in vivo: quantification of localized proton MR spectra. , 1993, Radiology.

[37]  R. Kauppinen,et al.  Decrease in brain choline‐containing compounds following a short period of global ischemia in gerbils as detected by 1H NMR spectroscopy in vivo , 1994, NMR in biomedicine.

[38]  T. Ebisu,et al.  N-Acetylaspartate as an in vivo Marker of Neuronal Viability in Kainate-Induced Status Epilepticus: 1H Magnetic Resonance Spectroscopic Imaging , 1994, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[39]  T. Ernst,et al.  Abnormal cerebral metabolite concentrations in patients with probable alzheimer disease , 1994, Magnetic resonance in medicine.

[40]  M. Brownstein,et al.  N‐Acetylation of L‐Aspartate in the Nervous System: Differential Distribution of a Specific Enzyme , 1985, Journal of neurochemistry.

[41]  R. Dijkhuizen,et al.  T1 and T2 relaxation times of the major 1H‐containing metabolites in rat brain after focal ischemia , 1995, NMR in biomedicine.